Product Description
a novel, tumor-targeted, systemic gene therapy agent for cancer
Mechanisms of Action: Gene Therapy,RB94
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Amgen
Company Location: THOUSAND OAKS CA 91320
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Retinoblastoma|Bladder Cancer|Prostate Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SGT94-01 | P1 |
Completed |
Retinoblastoma|Prostate Cancer|Bladder Cancer |
2015-12-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|